A

n influential group of clinicians and scientists has come out against a new use for blood-thinning drugs in draft guidelines that could complicate the commercial launch of a recently approved anticoagulant from Portola Pharmaceuticals (PTLA).

The Portola drug, a pill called Bevyxxa, won FDA approval in June to reduce the risk of dangerous blood clots in patients leaving the hospital after treatment for a medical (as opposed to a surgical) illness. The drug failed a phase 3 clinical trial when it didn’t show statistically significant benefits compared to an old generic. But Portola then re-analyzed the data and was able to convince regulators that Bevyxxa provided a benefit over the generic.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Adam, you are an idiot. As usual your articles are filled with hypothesized theories that are based on no facts. You do this because that’s what sells making you a disgrace to journalism. PTLA is unrelated to anticoagulants.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.